Drug Discovery World

MAY 28, 2024

The growth will in part by driven by an increase in the use of imaging modalities in drug research and development. Download this exclusive eBook to learn more about: How new imaging modalities are supporting the development of new therapies for cancer and neurodegenerative diseases. from 2023 to 2030.

Drugs 130

Drugs Clinical Trials Marketing Disease 130

Advarra

AUGUST 16, 2022

A rare, or orphan, disease by definition affects a small percentage of the population — fewer than 200,000 people in the U.S. But the numbers add up, and taken together, rare diseases impact an estimated 30 million Americans. Since then, the FDA has significantly changed its approach to rare and orphan diseases.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

Crown Bioscience

AUGUST 2, 2021

In this blog we will explore immune-mediated inflammatory diseases (IMIDs) —which represent a diverse group of conditions characterized by an excessive and/or inappropriate immune response.

Disease 52

Disease Drug Development Immune Response Drugs 52

DrugBank

AUGUST 20, 2024

The world of drug discovery is in a state of transformation, with advancements in biotechnology opening doors to new possibilities for targeting previously "undruggable" disease mechanisms. We also explore why some disease-associated targets remain elusive and how recent innovations are changing that narrative.

Pharmaceuticals 73

Pharmaceuticals Therapies Research Disease 73

Drug Discovery World

MARCH 22, 2023

Strategic research partnerships bring together knowledge, expertise and technologies, allowing advancements in our understanding of diseases and therapeutics that would not be possible in isolation. The collaboration seeks to validate novel drug targets that are causally linked to clinical endpoints in Huntington’s disease.

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Small Molecule Licensing 130

DrugBank

MAY 15, 2024

Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded. Among these targets are proteins, receptors, and enzymes that are fundamental to disease mechanisms.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

Drug Target Review

OCTOBER 26, 2023

Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. Molecular Therapy 20 , 1831-1832 (2012).

Engineering 105

Engineering Virus Therapies Immune Response 105

Vial

MAY 20, 2024

In this article, we will define preclinical and clinical CROs, as well as highlight the unique needs and challenges of these organizations in their respective stages of drug research. What is a Pre-Clinical CRO? The global preclinical CRO market was estimated to be valued at US$5.7 billion in 2022 and is projected to reach US$10.2

Clinical Research 52

Clinical Research Research Clinical Trials Laboratories 52

Drug Discovery World

NOVEMBER 16, 2022

Think of a cell culture, where scientists can observe the growth of a cell in the body in an in-vitro setting, and gain an understanding of how they react to different drug compounds. Current research . That is very impactful right cause you’re getting a huge swathe of cancer therapies and immunotherapies with cancer.

Pharma Companies 243

Pharma Companies Science Research Drugs 243

Codon

JANUARY 21, 2024

Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., yellow fever, malaria, and dengue), evaluating new drugs or treatments, and studying pathogenesis, the process by which a disease develops. Why are challenge trials becoming more popular?

Vaccine 117

Vaccine Trials Disease Virus 117

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

This improvement stems from several factors, including the FDA’s emergency use authorization (EUA) of a number of therapies found to be safe and effective for COVID-19. ACTIV was founded last April to accelerate drug research that typically requires more than a decade of clinical ups and downs to develop a safe, effective therapy.

Clinical Trials 52

Clinical Trials Hospitals Vaccine Trials 52

Drug Discovery World

FEBRUARY 9, 2023

At the same time, we are developing a better understanding of disease pathology, leading to a more complicated picture of how diseases manifest. The first is that in-roads made in decoding the complexity of human disease will make drug discovery more difficult and costly, limiting the potential to develop new life-saving therapies.

Drugs 130

Drugs Pharmaceuticals Disease Treatment 130

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care. ” The Journal of infectious diseases 219.11 (2018): 1786-1798.

Bioinformatics 130

Bioinformatics RNA Vaccine Clinical Trials 130

Drug Discovery World

AUGUST 8, 2023

The centre was established in 2013 at the university with the goal to discover novel drugs to fight against life threatening infectious diseases including tuberculosis (TB), Acquired Immuno Deficiency syndrome (AIDS), Dengue and non-infectious diseases including cancer, diabetes and more 9.

Research 130

Research Pharmacy Pharmaceuticals Government 130

Agency IQ

JUNE 9, 2023

The problems: Although the current regulation stimulated orphan drug research, it didn’t do enough The regulation fostered development of medicines for rare diseases since implementation, but not enough. However, 95% of the over 6,000 recognized orphan diseases still have no treatment options.

Marketing 40

Marketing Biosimilars Regulations Drugs 40

The Pharma Data

APRIL 24, 2021

The COVID-19 pandemic highlights the importance of robust health systems to respond to disease outbreaks and to control other deadly diseases such as malaria. In 2020, we discovered another novel malaria therapy, INE963, which has an entirely new mechanism of action and is expected to begin clinical trials in 2021.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

JANUARY 26, 2021

percent) in patients taking therapy and 36 events (7.0 Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution. who require oxygen therapy due to COVID-19, OR.

Hospitals 52

Hospitals Treatment Long-Term Care Facilities Trials 52

Codon

JUNE 2, 2024

Without mouse models, we may never have developed polio and meningitis vaccines, organ transplants, GLP-1 drugs, gene therapies , or any other number of transformative treatments. Today, somewhere on the order of 30 million rodents are used yearly in biomedical research in the U.S. In a testimony in front of the U.S.

Laboratories 120

Laboratories Research Disease Science 120